We are in a new era of gene therapy, but the way the body views therapeutic genes introduced by AAV vectors as potential threats to human cells is anything but new. It remains a significant challenge. NxGEN technology overcomes this challenge, building stealthy AAV vectors that come in under the body’s immune radar to deliver their healing power without activating the body’s defenses.
Gene therapy is an investment for now and in the future. Can you afford to build your vectors without investing in NxGEN technology?